Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bensler LLC

Bensler LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 13.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,215 shares of the medical research company's stock after selling 3,489 shares during the quarter. Bensler LLC's holdings in Amgen were worth $6,051,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Amgen by 1.6% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,382 shares of the medical research company's stock worth $1,142,000 after acquiring an additional 67 shares in the last quarter. Tamar Securities LLC increased its position in Amgen by 8.6% in the fourth quarter. Tamar Securities LLC now owns 57,088 shares of the medical research company's stock worth $14,879,000 after purchasing an additional 4,537 shares during the last quarter. Perigon Wealth Management LLC increased its position in Amgen by 25.1% in the fourth quarter. Perigon Wealth Management LLC now owns 16,145 shares of the medical research company's stock worth $4,350,000 after purchasing an additional 3,236 shares during the last quarter. Jeppson Wealth Management LLC raised its stake in Amgen by 30.4% during the fourth quarter. Jeppson Wealth Management LLC now owns 3,487 shares of the medical research company's stock valued at $909,000 after purchasing an additional 812 shares in the last quarter. Finally, Matrix Asset Advisors Inc. NY lifted its position in Amgen by 96.0% during the fourth quarter. Matrix Asset Advisors Inc. NY now owns 93,022 shares of the medical research company's stock valued at $24,245,000 after purchasing an additional 45,573 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Wolfe Research started coverage on shares of Amgen in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Piper Sandler decreased their price objective on Amgen from $344.00 to $310.00 and set an "overweight" rating on the stock in a research report on Thursday, January 2nd. UBS Group lowered their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating for the company in a research note on Thursday, October 31st. Wells Fargo & Company decreased their price target on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a report on Friday, January 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $324.00 price objective on shares of Amgen in a research note on Friday. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $314.00.

Amgen Stock Down 0.9 %

NASDAQ:AMGN traded down $2.65 during trading hours on Tuesday, reaching $280.30. The company's stock had a trading volume of 2,735,291 shares, compared to its average volume of 3,086,947. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market capitalization of $150.67 billion, a P/E ratio of 35.89, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The stock has a 50 day moving average price of $271.47 and a two-hundred day moving average price of $305.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the company posted $4.96 EPS. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.40%. This is an increase from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.